RxDoctor Payments Data

Paul Unger, MD

Hematology & Oncology · Burlington, VTNPI 1053318766

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (34.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Avyxa Pharma, LLC at 33.6% of the total.

$12,262in general payments, 2019–2025

Across 26 payments — averaging $471.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avyxa Pharma, LLC$4K
  • Pharmacosmos Therapeutics Inc.$4K
  • AstraZeneca$3K
  • EMD Serono, Inc.$2K
  • Sobi, Inc$200
  • Merck$26
  • plus $13 from 1 others

What the payments were for

  • Consulting fees$4,19834%
  • Speaking & faculty fees$3,50029%
  • Travel & lodging$4,13034%
  • Food & beverage$4093%
  • Education$260%

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology & oncology providers in Vermontto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,955,533
Medicare patients
417
Services billed
153,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide26$680,677
EnjaymoSutimlimab-Jome26$589,920
Lenalidomide40$589,162
ImbruvicaIbrutinib24$392,124
BrukinsaZanubrutinib28$332,980
PomalystPomalidomide15$248,626
TagrissoOsimertinib Mesylate12$213,060
VenclextaVenetoclax39$201,680
Abiraterone Acetate29$160,139
EliquisApixaban64$57,240
InlytaAxitinib14$54,076
Enoxaparin Sodium19$6,216
Anastrozole251$5,614
Hydroxyurea59$1,765
Exemestane12$901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$2,782$213,06012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Vermonton file to place this against a meaningful peer group, so we don't.

Other hematology & oncology in Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →